|
Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Compound class:
Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial. A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5]. |
| References |
|
1. Anan C, Kim JK, Presta LG, Stewart T. (2009)
Anti-interferon-α antibodies. Patent number: US7582445. Assignee: Genentech, Inc.. Priority date: 22/02/2001. Publication date: 01/09/2009. |
|
2. Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA. (2001)
Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine, 15 (5): 250-60. [PMID:11594789] |
|
3. Kalunian KC. (2016)
Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?. Lupus, 25 (10): 1097-101. [PMID:27497254] |
|
4. Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis Jr JC, Kennedy WP. (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis, 75 (1): 196-202. [PMID:26038091] |
|
5. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. (2015)
Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab. Protein Sci, 24 (9): 1440-50. [PMID:26099203] |
